List view / Grid view
Subvisible particles in protein-based formulations can have different origins. Particles can be extrinsic (unexpected foreign material), intrinsic (from the production environment or primary packaging), and inherent (from the formulation). It is important that inherent particles (protein agglomerates) are distinguished from the other two types and that the extrinsic and intrinsic…
In this Formulation Development & Delivery In-Depth Focus: A report on the use of freeze-drying to develop orally disintegrating tablets; a review of mucosal drug delivery; an interview on drug delivery through the skin; and a profile of three analytical technologies used to develop drug delivery systems...
In this supplement, we've brought together a collection of interesting posters from leading companies in order to celebrate cutting-edge research in the pharmaceutical industry and to share with our readers some of the varied work being carried out by their colleagues...
In Issue #3 2017: In-Depth Focuses covering Raman Spectroscopy, Separations & Purifications, Formulation Development & Delivery; Guide To Testing Services; GMP and mutual recognition; Regulatory Insight; RMMs; Microbiology Series; and much more...
The FDA has approved the cryopreserved formulation of ReNeuron’s human retinal progenitor cell (hRPC) therapeutic candidate...
We caught up with Naghmana Bajwa, MD, Global Medical Affairs Haematology Lead at Shire to find out the latest in haemophilia disease research...
In the first large pragmatic trial of its kind in the United States, results from a study show that checking finger-stick blood sugars may not help diabetes patients who do not use insulin.
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
The challenge of efficiently delivering a drug to its site of action, while maintaining its efficacy and minimising its potential toxicity, has received much attention in recent years, with the growing use of complex and often delicate biological molecules as therapeutic agents...
Following the introduction of the concept of mucoadhesion in the 1980s, polymeric excipients became attractive for intense research purposes. Mucosal delivery as a non-invasive delivery pathway raised the bar.
1 June 2017 | By Niamh Marriott, Junior Editor
The European Medicines Agency (EMA) and the European Commission have published an information guide for healthcare professionals on biosimilar medicines...
30 May 2017 | By Quotient Clinical
Appointment supports Quotient’s strategy to further develop its global commercial footprint following two recent US acquisitions...
30 May 2017 | By Pasi Kemppainen, Executive Consultant, Pharma Digitalisation and Sammeli Liikkanen, Chief Digital Officer, Orion Pharma
Pharma Digitalisation Executive Consultant, Pasi Kemppainen, and Orion’s CDO Sammeli Liikkanen talk technologies, challenges and opportunities with the digitalisation of pharma…
26 May 2017 | By Ho-ung Kim, Head of Strategy and Operations Division for Celltrion Healthcare
We caught up with Celltrion Healthcare's Ho-ung Kim to find out how biosimilars cut costs, increase access to medicine and are ultimately changing the industry…
23 May 2017 | By Niamh Marriott, Junior Editor
Biosimilar medicines have dramatically increased patient access to biological medicines, according to the recently published QuintilesIMS report...
